Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 130 of 5804
-
AI coach takes on diabetes drug: can a smart lifestyle program beat tirzepatide?
Disease control Not yet recruitingThis multicenter randomized controlled trial will evaluate whether an AI-assisted intensive lifestyle intervention can improve weight and glycemic management in adults with obesity and newly diagnosed type 2 diabetes, compared with tirzepatide treatment and standard lifestyle man…
Phase: PHASE4 • Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug duo aims to keep advanced nasopharyngeal cancer in check
Disease control Recruiting nowThis multicenter randomized controlled Phase III trial assesses the efficacy and safety of becotatug vedotin plus anti-PD-1 antibody as maintenance therapy for recurrent/metastatic nasopharyngeal carcinoma. Eligible patients aged 18-75 must have stable disease or positive plasma …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New platform trial takes on NF2 tumors with multiple drug strategies
Disease control Not yet recruitingThis is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN). The study employs a basket design to assess treatment responses across four tumor typ…
Phase: PHASE2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a new drug outsmart resistant breast cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also …
Phase: PHASE2 • Sponsor: Chengdu SciMount Pharmatech Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Triple-Drug cocktail aims to wipe out stomach tumors before surgery
Disease control Not yet recruitingThis is a prospective, single-center, randomized controlled phase II clinical trial.It plans to enroll a total of 24 eligible patients with locally advanced gastric/gastroesophageal junction adenocarcinoma who are HER2-positive and have potential benefit from immunotherapy (PD-L1…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Race against time: can surgery within hours save brain bleed patients?
Disease control Recruiting nowMINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to either minimally invasive endoscopic SCUBA evacuation plus standard medical managem…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New bladder cancer drug aims to fight tumors without harming nerves
Disease control Not yet recruitingThe main goal of this clinical trial is to learn if a new targeted cancer drug called sacituzumab tirumotecan (sac-TMT) works to treat cancer while causing less nerve damage in patients with advanced urothelial carcinoma who have progressed on or could not tolerate previous treat…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New ointment aims to restore skin color in vitiligo
Disease control Not yet recruitingThis is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immunotherapy plus chemotherapy before surgery shows promise against tough stomach cancers
Disease control Recruiting nowTo evaluate the clinical efficacy of perioperative treatment with S-1 + oxaliplatin (SOX)+ HLX10 compared with SOX as the control in patients with cT3-4N1-3M0 PD-L1-positive (CPS ≥ 5) locally advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, in a placeb…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for bladder cancer patients: experimental drug combo aims to beat chemo
Disease control Recruiting nowThis is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive papillary-only non-muscle-invasive …
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a new Antibody-Lowering drug ease autoimmune brain inflammation?
Disease control Not yet recruitingThe POLARIS study is designed to evaluate how well efgartigimod PH20 SC may work (called "efficacy") and how safe it is for people diagnosed with Autoimmune Encephalitis (AIE). The study consists of 4 parts: in part A participants will receive efgartigimod SC; in part B, particip…
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental vaccine aims to clear precancerous cervical lesions without surgery
Disease control Not yet recruitingThis trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of SYS6026 at different doses compared to placebo in treating patients with HPV16 or 18-related high-grade cervical squamous intraepithel…
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo aims to silence hepatitis b virus
Disease control Recruiting nowA randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
Phase: PHASE2 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Immune protein G-CSF put to the test for unexplained recurrent miscarriage
Disease control Recruiting nowRecurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both dist…
Phase: PHASE2 • Sponsor: Fakih IVF Fertility Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Blood filter targets DNA to tame septic shock inflammation
Disease control Not yet recruitingSepsis continues to be a major global health concern, characterized by high morbidity and mortality rates. As a clinical syndrome characterized by a dysregulated systemic response to infection, its progression toward life-threatening organ dysfunction is driven by an array of sig…
Phase: NA • Sponsor: Sergey Savko • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Short burst of radiation before Immuno-Chemo may boost esophageal cancer response
Disease control Not yet recruitingNeoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Plus Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma This is a prospective, randomized, two-arm, parallel-group, multicenter, exploratory Phase II clinical trial. It aims to evaluate th…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
Disease control Not yet recruitingTo explore the efficacy and safety of first-line EGFR-TKI combined with Trastuzumab Rezetecan in advanced NSCLC patients harboring EGFR mutations with concomitant HER2 genomic alterations or HER2 protein expression (1+/2+/3+)
Phase: PHASE2 • Sponsor: Yongsheng Wang • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a new daily pill help young children with ADHD?
Disease control Recruiting nowThis study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to \<12 years with ADHD.
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New daily pill aims to rival semaglutide for diabetes and weight loss
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering me…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New diabetes drug aims to help those with kidney disease
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC